Bristol-Myers Squibb's $9-billion patent shielded as Indian court blocks biosimilar threat
Bristol-Myers Squibb secured an interim injunction to block Zydus Lifesciences' launch of its nivolumab biosimilar in India. The decision by the Delhi High Court protects BMS's $9 billion blockbuster cancer drug...To view the full article, register now.
Already a subscriber? Click here to view full article